此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Personalized Needs in Clostridium Difficile Infections (SPECIFY)

2017年10月3日 更新者:Evangelos J. Giamarellos-Bourboulis, M.D.、University of Athens

Scoring Personalized Needs in Clostridium Difficile Infections for Fidaxomixin Therapy

To develop a score that can predict early from diagnosis of Clostridium difficile infection (CDI) the risk for relapse and of unfavorable outcome. This score can be used in the future to identify patients will benefit from fidaxomicin treatment.

研究概览

详细说明

Medical world is nowadays witnessing a sudden increase of the incidence of infections by Clostridium difficile (DCI). This is due in part to the prolongation of survival of patients with major comorbidities like solid tumor malignancies and lymphomas but also to the widespread intake of proton pump inhibitors and of wide-spectrum antimicrobials. It is highly probable that isolates of C.define causing this pandemic are genetically different than isolates of the same species predominating 20 years ago. This hypothesis is developed based on data of the epidemiology of CDI: in old times administration of clindamycin and ampicillin were the main drivers of CDI; recent studies report fluoroquinolones, 2nd and 3rd generation cephalosporins and even vancomycin (i.e. a drug of choice for CDI) to be linked with the development of CDI.

One major hurdle in management of CDI is relapse; the risk of relapse is reported as 15-20% after the first episode; however it is geometrically increased to even 60-80% after the second episode. As a consequence, management of CDI becomes a major health problem.

Fidaxomicin is a novel compound active against species of C.dificille. Results of two recent double-blind, randomized, large scale clinical studies have shown that oral treatment for 10 days with fidaxomicin 200mg bid was non-inferior to oral treatment with vancomycin 125mg q6h. However, the risk of relapse after treatment with vancomycin was close to 25% and with fidaxomicin close to 15%. This difference was statistically significant in both trials outscoring the superiority of fidaxomicin over vancomycin for the management of CDI. Moreover, meta-analysis has shown a significant reduction in mortality by fidaxomicin.

Despite proven superiority, prescription of fidaxomicin is limited to few cases mostly due to high cost. In many countries prescription is restricted to cases of relapsing CDI. Clinical feeling coming both from post-marketing experience as well as from published evidence supports the use of fidaxomicin for cases with risk of death and overt risk of relapse. However, molecular analysis of the C.difficile pathogen cannot be used as a tool for the prediction of relapse since in relapse cases pathogens carry less than 2 single nucleotide variants of the initial isolate. SPECIFY is aiming to develop a score using both clinical and genetic and biomarker data that can efficiently discriminate patients at risk of severe CDI and at risk of relapse of CDI. This score can become in future a tool to discriminate patients at need for treatment with fidaxomicin instead of traditional treatment with metronidazole/vancomycin.

研究类型

观察性的

注册 (实际的)

150

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Athens、希腊、10676
        • 5th Department of Internal Medicine, Evangelismos Athens General Hospital
      • Athens、希腊、11527
        • 1st Department of Internal Medicine, "G.Gennimatas" General hospital
      • Athens、希腊、11527
        • 1st Department of Internal Medicine, Laikon General Hospital
      • Athens、希腊、11527
        • 3rd Department of Internal Medicine, Sotiria General Hospital
      • Athens、希腊、12462
        • 4th Department of Internal Medicine, Attikon University Hospital
      • Athens、希腊、15126
        • 2nd Department of Internal Medicine, Sismanogleion General Hospital
      • Magoula、希腊、10918
        • 1st Department of Internal Medicine, Thriassio General Hospital
      • Magoula、希腊、10918
        • 2nd Department of Internal Medicine, Thriasio General Hospital
      • Maroúsi、希腊、15123
        • 2nd Department of Oncology, Mitera Hospital
      • Piraeus、希腊
        • Infections Unit Tzaneion General Hospital
      • Pátra、希腊、36504
        • Department of Internal Medicine, Patras University Hospital
      • Thessaloniki、希腊、54248
        • 1st Department of Internal Medicine, AHEPA University Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

概率样本

研究人群

Patients with Clostridium difficile-associated diarrhea

描述

Inclusion Criteria:

  1. Age equal to or more than 18 years
  2. Both genders
  3. Diarrhea defined as at least 3 episodes of unformed stools in the last 24 hours according to the Bristol stool chart
  4. Presence of C.difficile in stool. This is defined as any stool sample positive for the presence of glutamate dehydrogenase (GDH) and for the presence of toxin A and/or B.

Exclusion Criteria:

1. No exclusion criteria exist

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:仅案例
  • 时间观点:预期

队列和干预

团体/队列
干预/治疗
Clostridium difficile infection
Patients with Clostridium difficile-associated diarrhea for development of biomarkers
Blood sampling
其他名称:
  • Single nucleotide polymorphisms
  • Serum cytokines

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Definition of prognostic biomarker
大体时间:12 months
Patients with positive score and unfavorable outcome. Unfavorable outcome is defined as at least one of the following: a) number of patients with severe infection at disease onset; b) number of patients who progress into severe infection; c) number of patients with disease recurrence; and d) number of patients who die
12 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Athanasios Skoutelis, MD、Evangelismos Athens General Hospital
  • 学习椅:Evangelos J Giamarellos-Bourboulis, MD, PhD、Attikon Hospital
  • 首席研究员:George Chrysos, MD, PhD、Tzaneion Piraeus General Hospital
  • 首席研究员:Styliani Symbardi, MD, PhD、Thriassio Elefsis General Hospital
  • 首席研究员:Zoi Alexiou, MD, PhD、Thriassio Elefsis General Hospital
  • 首席研究员:Kostantinos Syrigos, MD, PhD、Sotiria General Hospital
  • 首席研究员:George Daikos, MD, PhD、Laikon Athens General Hospital
  • 首席研究员:Panagiotis Gargalianos, MD, PhD、G.Gennimatas Athens General Hospital
  • 首席研究员:Malvina Lada, MD, PhD、Sismanogleion General Hospital
  • 首席研究员:Charalambos Gogos, MD, PhD、University Hospital of Patras
  • 首席研究员:Ilias Athanasiadis, MD, PhD、Mitera General Hospital
  • 首席研究员:Symeon Metallidis, MD, PhD、AHEPA Thessaloniki University Hospital

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2015年10月1日

初级完成 (实际的)

2016年12月1日

研究完成 (实际的)

2017年10月1日

研究注册日期

首次提交

2015年10月8日

首先提交符合 QC 标准的

2015年10月9日

首次发布 (估计)

2015年10月12日

研究记录更新

最后更新发布 (实际的)

2017年10月5日

上次提交的符合 QC 标准的更新

2017年10月3日

最后验证

2017年10月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅